Latest filing published 27 Aug 2021 for Kymera Therapeutics, Inc., €575k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Richard Chesworth: trading record in brief
Richard Chesworth (senior executive) discloses dealings in Kymera Therapeutics, Inc. to SEC (Form 4). We count 7 filings; the first trade dates from 17 August 2021 and the latest from 27 August 2021.
On the market, this insider has only sold: 5 sales, €4.1M in total. Besides market trades, the filings include 2 option exercises.
Most recently, on 27 August 2021, the filings show an open-market sale worth €1.7M in Kymera Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Richard Chesworth
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 33,779 shares@ US$20.0038.4% of flowCommon StockSEC:0001209191-21-053642:0
- 54,000 shares@ US$20.0061.6% of flowCommon StockSEC:0000899243-21-033638:0
2 of 2 declarations
